Date: 09 Feb 2012
Neoadjuvant Chemotherapy for Invasive Bladder Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Neoadjuvant cisplatin-based combination chemotherapy is an established standard for resectable muscle-invasive bladder cancer, a disease with a pattern of predominantly distant and early recurrences. Pathologic complete remission appears to be an intermediate surrogate for survival when employing combination chemotherapy. Moreover, baseline host and tumor tissue studies may enable the discovery of biomarkers predictive of activity. The neoadjuvant setting also provides a window of opportunity to evaluate novel biologic agents or rational combinations of biologic agents to obtain a signal of biologic activity. The residual tumor after neoadjuvant therapy may be exploited to study the mechanism of action and resistance. Cisplatin-ineligible patients warrant the evaluation of tolerable neoadjuvant regimens. Given that bladder cancer is characterized by initial localized presentation in the vast majority of cases, the paradigm of neoadjuvant therapy may expedite the development of novel systemic agents.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.PubMed
Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Canc Inst. 2007;99:167–70.CrossRef
Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–9.PubMed
Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–46.PubMed
Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–81.PubMed
Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol. (Meeting Abstracts). 2007 June 20, 2007;25:LBA5030-.
Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011 May 4.
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999 Aug 14;354:533–40.
•• Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol Offic J Am Soc Clin Oncol. 2011 Jun 1;29:2171–7. This is the recent publication of an update of the MRC randomized phase III trial that evaluated neoadjuvant CMV and demonstrated improved survival. CrossRef
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug;48:202–5; discussion 5–6.
Smith DC, Grivas P, Daignault, et al. A phase II trial of neoadjuvant ABI-007, carboplatin and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder genitourinary cancer symposium 2011, Abstract 244.
Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. Jul 1;116:3127–34.
• Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15;115:4104–9. This is a retrospective analysis of the SWOG-8710 phase 3 trial that evaluated neoadjuvant MVAC and analyzed a variety of pathologic endpoints for association with survival. PubMedCrossRef
Feifer A, Taylor J, Shouery M, et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder. J Clin Oncol. 2011;29 (suppl 7; abstr 240).
Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459–64. discussion 64-7.PubMed
Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994;152:81–4.PubMed
Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol Offic J Am Soc Clin Oncol. 2001;19:4005–13.
Jin JO, Lehmann J, Taxy J, et al. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Canc. 2006;5:150–4.CrossRef
Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. J Clin Oncol. 2008;26(May 20 suppl; abstr 5023).
Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol. 2010;28:18 s(suppl; abstr LBA4518).
Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol Offic J Am Soc Clin Oncol. 2011;29:3443–9.CrossRef
Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Canc Res Offic J Am Assoc Canc Res. Sep 1;16:4461–7.
Sonpavde G, Khan MM, Svatek RS, et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU International. Nov 19.
Sonpavde G, Shariat SF. Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed. Cancer. 2011 Jul 5.
Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol Offic J Am Soc Clin Oncol. 2009;27:4314–20.CrossRef
Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. Feb;12:137–43.
Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998;58:1298–304.PubMed
Lonn U, Lonn S, Friberg S, Nilsson B, Silfversward C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res. 1995;1:1189–94.PubMed
Blick C, Hall P, Pwint T, et al. Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle invasive transitional cell carcinoma of the bladder. Genitourin Canc Symp. 2011;Abstract 235.
Mitra N, Monk JP, Pohar KS, et al. Early outcomes with neoadjuvant high-dose intensity methotrexate, binblastine, doxorubicin and cisplatin (HD-MVAC) or gemcitabine and cisplatin (G-C) in muscle-invasive urothelial carcinoma of the bladder: a single-institution experience genitourinar cancer symposium 2011, Abstract 280.
Chaudhary UB, Golshayan A, Brisendine A, et al. Phase II trial of neoadjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder genitourinar cancer symposium 2011, Abstract 276.
Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Canc Inst. 2008;100:672–9.CrossRef
Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91:844–9.PubMed
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 3098. J Clin Oncol. 2009;27:5634–9.PubMedCrossRef
Sonpavde G, Khan MM, Lerner SP, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. Feb;185:456–61.
Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU International. Aug;106:349–56.
Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. Jan;22:139–44.
- Neoadjuvant Chemotherapy for Invasive Bladder Cancer
Current Urology Reports
Volume 13, Issue 2 , pp 136-146
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Bladder cancer
- Neoadjuvant therapy
- Industry Sectors
- Author Affiliations
- 1. Texas Oncology, the Michael E. DeBakey Veterans Affairs Medical Center, Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, 77030, USA
- 2. San Camillo and Forlanini Hospitals, Padiglione Flajani I, Circonvallazione Gianicolense 87, 00152, Rome, Italy